Scroll to Top

Volume : IV, Issue : XI, December - 2014

ROLE OF SOLUBLE LR11 AND APOLIPOPROTEINS A1&B IN THE PROGRESSION OF DIABETIC RETINOPATHY

Mona A. Abdel Hamid, Leqaa A. Moemen, Nervana A. Khalaf, Hany M. Labib, HazemHelmy and Manal H. Abuelea

By : Laxmi Book Publication

Abstract :

To evaluate the serum and vitreous fluid levels of soluble lipoprotein receptor LR11 (sLR11), a novel circulating marker for proliferative diabetic retinopathy (PDR), in patients with PDR and non-PDR (NPDR) in comparison to those in patients with non-diabetic ocular diseases. Also, we evaluate serum levels of apo A1 and B in all studied groups. Fifteen NPDR and 20 PDR cases were included in this study. Ten subjects with macular hole were served as a control group. The sLR11 and apo A1 & B levels were determined by sandwich enzyme-linked immune-sorbent assay. The serumsLR11 levels in the PDR and NPDR groups were significantly higher than those in the control subjects. The vitreous fluid levels of sLR11 were significantly elevated in the PDR while in the NPDR group; it was higher than in the control group, but not statistically significant. Serum apolipoprotein A1 is significantly decreased in PDR compared to NPDR patients, while serum apolipoprotein B were significantly elevated in PDR patients compared to NPDR.sLR11 may be a novel predictor for the early development of PDR patients prior to the increase in the circulating levels in diabetics. Serum apoAI, apoB levels, and the apoB-to-apoAI ratio were consistently associated with the presence of diabetic retinopathy and severity of diabetic retinopathy.

Keywords :


Article :


Cite This Article :

Mona A. Abdel Hamid, Leqaa A. Moemen, Nervana A. Khalaf, Hany M. Labib, HazemHelmy and Manal H. Abuelea(2014). ROLE OF SOLUBLE LR11 AND APOLIPOPROTEINS A1&B IN THE PROGRESSION OF DIABETIC RETINOPATHY. Indian Streams Research Journal, Vol. IV, Issue. XI, http://isrj.org/UploadedData/5764.pdf

References :

  1. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  2. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  3. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  4. J Neurosci 26: 1596–1603
  5. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  6. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  7. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  8. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  9. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  10. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  11. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  12. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  13. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  14. Invest., 118: 2733–2746
  15. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  16. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  17. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  18. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  19. factor-alpha. Circ. Res., 100: 381–390.
  20. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  21. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  22. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  23. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  24. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  25. Invest., 118: 2733–2746
  26. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  27. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  28. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  29. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  30. J Neurosci 26: 1596–1603
  31. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  32. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  33. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  34. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  35. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  36. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  37. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  38. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  39. factor-alpha. Circ. Res., 100: 381–390.
  40. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  41. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  42. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  43. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  44. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  45. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  46. J Neurosci 26: 1596–1603
  47. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  48. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  49. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  50. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  51. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  52. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  53. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  54. factor-alpha. Circ. Res., 100: 381–390.
  55. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  56. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  57. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  58. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  59. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  60. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  61. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  62. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  63. J Neurosci 26: 1596–1603
  64. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  65. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  66. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  67. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  68. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  69. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  70. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  71. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  72. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  73. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  74. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  75. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  76. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  77. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  78. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  79. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  80. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  81. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  82. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  83. plasma levels. J Intern. Med., 259: 437–446.
  84. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  85. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  86. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  87. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  88. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  89. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  90. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  91. factor-alpha. Circ. Res., 100: 381–390.
  92. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  93. J Neurosci 26: 1596–1603
  94. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  95. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  96. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  97. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  98. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  99. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  100. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  101. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  102. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  103. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  104. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  105. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  106. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  107. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  108. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  109. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  110. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  111. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  112. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  113. factor-alpha. Circ. Res., 100: 381–390.
  114. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  115. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  116. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  117. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  118. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  119. factor-alpha. Circ. Res., 100: 381–390.
  120. micro-vascular complications. JAMA; 303: 2291–2292.
  121. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  122. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  123. Ophthalmol. Vis. Sci., 49: 2679–2685.
  124. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  125. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  126. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  127. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  128. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  129. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  130. factor-alpha. Circ. Res., 100: 381–390.
  131. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  132. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  133. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  134. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  135. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  136. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  137. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  138. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  139. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  140. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  141. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  142. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  143. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  144. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  145. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  146. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  147. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  148. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  149. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  150. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  151. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  152. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  153. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  154. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  155. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  156. Invest., 118: 2733–2746
  157. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  158. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  159. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  160. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  161. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  162. factor-alpha. Circ. Res., 100: 381–390.
  163. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  164. J Neurosci 26: 1596–1603
  165. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  166. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  167. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  168. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  169. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  170. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  171. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  172. J Neurosci 26: 1596–1603
  173. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  174. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  175. Ed. Totowa, NJ, Humana Press, , p. 465–482
  176. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  177. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  178. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  179. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  180. Ed. Totowa, NJ, Humana Press, , p. 465–482
  181. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  182. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  183. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  184. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  185. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  186. Invest., 118: 2733–2746
  187. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  188. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  189. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  190. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  191. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  192. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  193. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  194. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  195. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  196. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  197. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  198. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  199. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  200. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  201. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  202. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  203. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  204. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  205. plasma levels. J Intern. Med., 259: 437–446.
  206. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  207. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  208. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  209. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  210. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  211. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  212. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  213. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  214. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  215. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  216. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  217. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  218. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  219. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  220. plasma levels. J Intern. Med., 259: 437–446.
  221. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  222. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  223. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  224. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  225. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  226. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  227. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  228. Invest., 118: 2733–2746
  229. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  230. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  231. J Neurosci 26: 1596–1603
  232. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  233. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  234. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  235. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  236. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  237. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  238. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  239. J Neurosci 26: 1596–1603
  240. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  241. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  242. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  243. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  244. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  245. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  246. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  247. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  248. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  249. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  250. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  251. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  252. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  253. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  254. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  255. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  256. J Neurosci 26: 1596–1603
  257. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  258. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  259. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  260. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  261. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  262. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  263. properties of HDL. Circ. Res., 95: 764–772.
  264. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  265. 1319–1333.
  266. Am J Ophthalmol; 141:446–455.
  267. micro-vascular complications. JAMA; 303: 2291–2292.
  268. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  269. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  270. Ophthalmol. Vis. Sci., 49: 2679–2685.
  271. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  272. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  273. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  274. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  275. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  276. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  277. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  278. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  279. micro-vascular complications. JAMA; 303: 2291–2292.
  280. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  281. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  282. Ophthalmol. Vis. Sci., 49: 2679–2685.
  283. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  284. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  285. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  286. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  287. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  288. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  289. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  290. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  291. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  292. micro-vascular complications. JAMA; 303: 2291–2292.
  293. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  294. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  295. Ophthalmol. Vis. Sci., 49: 2679–2685.
  296. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  297. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  298. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  299. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  300. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  301. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  302. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  303. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  304. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  305. properties of HDL. Circ. Res., 95: 764–772.
  306. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  307. 1319–1333.
  308. Am J Ophthalmol; 141:446–455.
  309. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  310. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  311. properties of HDL. Circ. Res., 95: 764–772.
  312. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  313. 1319–1333.
  314. Am J Ophthalmol; 141:446–455.
  315. micro-vascular complications. JAMA; 303: 2291–2292.
  316. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  317. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  318. Ophthalmol. Vis. Sci., 49: 2679–2685.
  319. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  320. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  321. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  322. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  323. micro-vascular complications. JAMA; 303: 2291–2292.
  324. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  325. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  326. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  327. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  328. J Neurosci 26: 1596–1603
  329. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  330. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  331. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  332. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  333. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  334. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  335. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  336. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  337. J Neurosci 26: 1596–1603
  338. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  339. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  340. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  341. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  342. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  343. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  344. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  345. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  346. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  347. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  348. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  349. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  350. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  351. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  352. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  353. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  354. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  355. properties of HDL. Circ. Res., 95: 764–772.
  356. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  357. 1319–1333.
  358. Am J Ophthalmol; 141:446–455.
  359. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  360. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  361. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  362. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  363. Invest., 118: 2733–2746
  364. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  365. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  366. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  367. Ophthalmol. Vis. Sci., 49: 2679–2685.
  368. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  369. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  370. Ed. Totowa, NJ, Humana Press, , p. 465–482
  371. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  372. factor-alpha. Circ. Res., 100: 381–390.
  373. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  374. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  375. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  376. plasma levels. J Intern. Med., 259: 437–446.
  377. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  378. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  379. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  380. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  381. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  382. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  383. Ed. Totowa, NJ, Humana Press, , p. 465–482
  384. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  385. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  386. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  387. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  388. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  389. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  390. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  391. properties of HDL. Circ. Res., 95: 764–772.
  392. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  393. 1319–1333.
  394. Am J Ophthalmol; 141:446–455.
  395. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  396. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  397. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  398. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  399. J Neurosci 26: 1596–1603
  400. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  401. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  402. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  403. Invest., 118: 2733–2746
  404. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  405. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  406. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  407. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  408. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  409. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  410. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  411. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  412. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  413. J Neurosci 26: 1596–1603
  414. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  415. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  416. Invest., 118: 2733–2746
  417. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  418. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  419. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  420. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  421. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  422. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  423. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  424. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  425. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  426. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  427. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  428. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  429. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  430. Ed. Totowa, NJ, Humana Press, , p. 465–482
  431. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  432. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  433. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  434. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  435. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  436. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  437. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  438. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  439. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  440. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  441. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  442. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  443. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  444. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  445. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  446. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  447. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  448. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  449. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  450. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  451. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  452. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  453. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  454. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  455. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  456. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  457. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  458. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  459. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  460. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  461. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  462. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  463. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  464. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  465. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  466. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  467. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  468. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  469. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  470. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  471. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  472. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  473. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  474. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  475. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  476. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  477. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  478. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  479. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  480. Invest., 118: 2733–2746
  481. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  482. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  483. plasma levels. J Intern. Med., 259: 437–446.
  484. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  485. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  486. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  487. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  488. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  489. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  490. factor-alpha. Circ. Res., 100: 381–390.
  491. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  492. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  493. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  494. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  495. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  496. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  497. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  498. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  499. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  500. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  501. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  502. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  503. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  504. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  505. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  506. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  507. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  508. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  509. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  510. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  511. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  512. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  513. Ed. Totowa, NJ, Humana Press, , p. 465–482
  514. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  515. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  516. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  517. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  518. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  519. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  520. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  521. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  522. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  523. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  524. plasma levels. J Intern. Med., 259: 437–446.
  525. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  526. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  527. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  528. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  529. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  530. plasma levels. J Intern. Med., 259: 437–446.
  531. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  532. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  533. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  534. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  535. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  536. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  537. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  538. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  539. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  540. micro-vascular complications. JAMA; 303: 2291–2292.
  541. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  542. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  543. Ophthalmol. Vis. Sci., 49: 2679–2685.
  544. micro-vascular complications. JAMA; 303: 2291–2292.
  545. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  546. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  547. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  548. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  549. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  550. Ed. Totowa, NJ, Humana Press, , p. 465–482
  551. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  552. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  553. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  554. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  555. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  556. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  557. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  558. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  559. micro-vascular complications. JAMA; 303: 2291–2292.
  560. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  561. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  562. Ophthalmol. Vis. Sci., 49: 2679–2685.
  563. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  564. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  565. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  566. Ophthalmol. Vis. Sci., 49: 2679–2685.
  567. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  568. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  569. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  570. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  571. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  572. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  573. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  574. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  575. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  576. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  577. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  578. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  579. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  580. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  581. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  582. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  583. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  584. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  585. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  586. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  587. plasma levels. J Intern. Med., 259: 437–446.
  588. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  589. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  590. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  591. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  592. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  593. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  594. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  595. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  596. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  597. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  598. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  599. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  600. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  601. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  602. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  603. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  604. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  605. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  606. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  607. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  608. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  609. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  610. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  611. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  612. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  613. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  614. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  615. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  616. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  617. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  618. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  619. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  620. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  621. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  622. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  623. plasma levels. J Intern. Med., 259: 437–446.
  624. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  625. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  626. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  627. Ed. Totowa, NJ, Humana Press, , p. 465–482
  628. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  629. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  630. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  631. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  632. micro-vascular complications. JAMA; 303: 2291–2292.
  633. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  634. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  635. Ophthalmol. Vis. Sci., 49: 2679–2685.
  636. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  637. micro-vascular complications. JAMA; 303: 2291–2292.
  638. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  639. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  640. Ophthalmol. Vis. Sci., 49: 2679–2685.
  641. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  642. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  643. plasma levels. J Intern. Med., 259: 437–446.
  644. factor-alpha. Circ. Res., 100: 381–390.
  645. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  646. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  647. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  648. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  649. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  650. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  651. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  652. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  653. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  654. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  655. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  656. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  657. plasma levels. J Intern. Med., 259: 437–446.
  658. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  659. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  660. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  661. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  662. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  663. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  664. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  665. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  666. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  667. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  668. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  669. J Neurosci 26: 1596–1603
  670. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  671. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  672. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  673. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  674. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  675. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  676. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  677. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  678. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  679. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  680. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  681. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  682. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  683. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  684. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  685. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  686. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  687. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  688. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  689. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  690. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  691. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  692. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  693. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  694. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  695. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  696. plasma levels. J Intern. Med., 259: 437–446.
  697. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  698. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  699. Ed. Totowa, NJ, Humana Press, , p. 465–482
  700. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  701. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  702. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  703. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  704. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  705. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  706. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  707. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  708. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  709. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  710. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  711. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  712. properties of HDL. Circ. Res., 95: 764–772.
  713. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  714. 1319–1333.
  715. Am J Ophthalmol; 141:446–455.
  716. micro-vascular complications. JAMA; 303: 2291–2292.
  717. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  718. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  719. Ophthalmol. Vis. Sci., 49: 2679–2685.
  720. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  721. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  722. properties of HDL. Circ. Res., 95: 764–772.
  723. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  724. 1319–1333.
  725. Am J Ophthalmol; 141:446–455.
  726. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  727. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  728. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  729. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  730. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  731. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  732. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  733. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  734. factor-alpha. Circ. Res., 100: 381–390.
  735. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  736. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  737. plasma levels. J Intern. Med., 259: 437–446.
  738. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  739. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  740. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  741. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  742. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  743. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  744. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  745. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  746. Ed. Totowa, NJ, Humana Press, , p. 465–482
  747. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  748. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  749. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  750. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  751. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  752. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  753. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  754. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  755. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  756. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  757. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  758. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  759. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  760. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  761. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  762. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  763. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  764. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  765. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  766. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  767. micro-vascular complications. JAMA; 303: 2291–2292.
  768. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  769. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  770. Ophthalmol. Vis. Sci., 49: 2679–2685.
  771. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  772. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  773. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  774. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  775. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  776. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  777. factor-alpha. Circ. Res., 100: 381–390.
  778. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  779. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  780. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  781. Ed. Totowa, NJ, Humana Press, , p. 465–482
  782. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  783. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  784. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  785. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  786. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  787. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  788. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  789. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  790. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  791. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  792. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  793. micro-vascular complications. JAMA; 303: 2291–2292.
  794. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  795. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  796. Ophthalmol. Vis. Sci., 49: 2679–2685.
  797. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  798. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  799. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  800. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  801. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  802. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  803. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  804. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  805. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  806. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  807. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  808. micro-vascular complications. JAMA; 303: 2291–2292.
  809. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  810. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  811. Ophthalmol. Vis. Sci., 49: 2679–2685.
  812. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  813. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  814. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  815. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  816. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  817. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  818. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  819. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  820. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  821. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  822. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  823. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  824. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  825. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  826. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  827. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  828. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  829. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  830. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  831. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  832. J Neurosci 26: 1596–1603
  833. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  834. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  835. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  836. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  837. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  838. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  839. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  840. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  841. Ed. Totowa, NJ, Humana Press, , p. 465–482
  842. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  843. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  844. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  845. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  846. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  847. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  848. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  849. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  850. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  851. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  852. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  853. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  854. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  855. Invest., 118: 2733–2746
  856. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  857. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  858. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  859. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  860. Ophthalmol. Vis. Sci., 49: 2679–2685.
  861. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  862. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  863. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  864. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  865. factor-alpha. Circ. Res., 100: 381–390.
  866. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  867. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  868. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  869. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  870. factor-alpha. Circ. Res., 100: 381–390.
  871. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  872. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  873. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  874. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  875. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  876. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  877. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  878. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  879. properties of HDL. Circ. Res., 95: 764–772.
  880. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  881. 1319–1333.
  882. Am J Ophthalmol; 141:446–455.
  883. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  884. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  885. micro-vascular complications. JAMA; 303: 2291–2292.
  886. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  887. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  888. Ophthalmol. Vis. Sci., 49: 2679–2685.
  889. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  890. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  891. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  892. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  893. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  894. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  895. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  896. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  897. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  898. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  899. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  900. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  901. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  902. properties of HDL. Circ. Res., 95: 764–772.
  903. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  904. 1319–1333.
  905. Am J Ophthalmol; 141:446–455.
  906. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  907. 1319–1333.
  908. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  909. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  910. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  911. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  912. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  913. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  914. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  915. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  916. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  917. Ed. Totowa, NJ, Humana Press, , p. 465–482
  918. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  919. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  920. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  921. plasma levels. J Intern. Med., 259: 437–446.
  922. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  923. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  924. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  925. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  926. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  927. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  928. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  929. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  930. J Neurosci 26: 1596–1603
  931. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  932. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  933. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  934. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  935. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  936. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  937. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  938. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  939. properties of HDL. Circ. Res., 95: 764–772.
  940. Am J Ophthalmol; 141:446–455.
  941. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  942. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  943. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  944. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  945. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  946. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  947. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  948. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  949. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  950. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  951. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  952. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  953. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  954. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  955. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  956. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  957. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  958. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  959. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  960. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  961. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  962. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  963. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  964. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  965. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  966. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  967. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  968. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  969. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  970. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  971. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  972. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  973. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  974. micro-vascular complications. JAMA; 303: 2291–2292.
  975. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  976. J Neurosci 26: 1596–1603
  977. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  978. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  979. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  980. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  981. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  982. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  983. Ophthalmol. Vis. Sci., 49: 2679–2685.
  984. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  985. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  986. plasma levels. J Intern. Med., 259: 437–446.
  987. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  988. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  989. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  990. properties of HDL. Circ. Res., 95: 764–772.
  991. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  992. 1319–1333.
  993. Am J Ophthalmol; 141:446–455.
  994. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  995. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  996. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  997. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  998. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  999. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1000. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1001. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1002. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1003. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1004. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1005. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1006. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1007. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1008. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1009. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1010. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1011. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1012. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1013. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1014. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1015. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1016. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1017. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1018. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1019. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1020. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1021. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1022. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1023. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1024. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1025. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1026. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  1027. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  1028. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  1029. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  1030. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1031. Invest., 118: 2733–2746
  1032. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1033. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1034. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1035. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1036. Invest., 118: 2733–2746
  1037. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1038. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1039. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1040. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1041. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1042. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1043. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1044. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1045. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1046. Invest., 118: 2733–2746
  1047. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1048. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1049. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1050. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1051. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1052. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1053. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1054. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1055. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1056. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1057. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1058. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1059. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1060. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1061. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1062. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1063. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1064. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1065. factor-alpha. Circ. Res., 100: 381–390.
  1066. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1067. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1068. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1069. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1070. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1071. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1072. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1073. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1074. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1075. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1076. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  1077. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  1078. plasma levels. J Intern. Med., 259: 437–446.
  1079. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  1080. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  1081. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  1082. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1083. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1084. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1085. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1086. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1087. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1088. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1089. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1090. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1091. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1092. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1093. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1094. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1095. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1096. factor-alpha. Circ. Res., 100: 381–390.
  1097. factor-alpha. Circ. Res., 100: 381–390.
  1098. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1099. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1100. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1101. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1102. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1103. Invest., 118: 2733–2746
  1104. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1105. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1106. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1107. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1108. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1109. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1110. micro-vascular complications. JAMA; 303: 2291–2292.
  1111. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1112. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1113. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1114. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1115. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1116. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1117. factor-alpha. Circ. Res., 100: 381–390.
  1118. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1119. properties of HDL. Circ. Res., 95: 764–772.
  1120. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  1121. 1319–1333.
  1122. Am J Ophthalmol; 141:446–455.
  1123. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1124. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1125. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1126. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1127. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1128. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1129. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1130. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  1131. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  1132. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1133. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1134. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1135. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1136. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1137. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1138. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1139. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1140. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1141. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1142. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1143. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1144. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1145. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1146. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  1147. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  1148. plasma levels. J Intern. Med., 259: 437–446.
  1149. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1150. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1151. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1152. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1153. micro-vascular complications. JAMA; 303: 2291–2292.
  1154. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1155. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  1156. J Neurosci 26: 1596–1603
  1157. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  1158. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  1159. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  1160. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  1161. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  1162. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  1163. plasma levels. J Intern. Med., 259: 437–446.
  1164. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  1165. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  1166. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1167. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1168. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1169. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1170. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1171. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  1172. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1173. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1174. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1175. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  1176. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  1177. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1178. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1179. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1180. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1181. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1182. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1183. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1184. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1185. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  1186. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  1187. factor-alpha. Circ. Res., 100: 381–390.
  1188. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1189. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1190. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1191. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1192. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1193. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1194. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1195. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1196. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1197. Invest., 118: 2733–2746
  1198. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1199. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1200. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1201. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  1202. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1203. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  1204. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  1205. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1206. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1207. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1208. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1209. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1210. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1211. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1212. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1213. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1214. factor-alpha. Circ. Res., 100: 381–390.
  1215. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  1216. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  1217. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1218. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1219. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1220. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1221. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1222. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1223. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1224. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1225. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1226. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1227. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1228. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1229. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1230. factor-alpha. Circ. Res., 100: 381–390.
  1231. factor-alpha. Circ. Res., 100: 381–390.
  1232. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1233. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1234. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1235. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1236. properties of HDL. Circ. Res., 95: 764–772.
  1237. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  1238. 1319–1333.
  1239. Am J Ophthalmol; 141:446–455.
  1240. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1241. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1242. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1243. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1244. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  1245. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  1246. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  1247. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  1248. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1249. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1250. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1251. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1252. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1253. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1254. micro-vascular complications. JAMA; 303: 2291–2292.
  1255. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  1256. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  1257. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1258. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1259. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1260. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1261. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1262. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1263. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1264. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1265. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1266. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1267. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1268. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1269. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1270. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1271. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1272. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1273. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1274. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1275. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1276. properties of HDL. Circ. Res., 95: 764–772.
  1277. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  1278. 1319–1333.
  1279. Am J Ophthalmol; 141:446–455.
  1280. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1281. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1282. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1283. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1284. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1285. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1286. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1287. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1288. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1289. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1290. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1291. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1292. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1293. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1294. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1295. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1296. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1297. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1298. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1299. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1300. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1301. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1302. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1303. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1304. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  1305. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  1306. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  1307. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  1308. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1309. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  1310. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  1311. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1312. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1313. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1314. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1315. micro-vascular complications. JAMA; 303: 2291–2292.
  1316. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1317. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1318. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1319. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1320. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  1321. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  1322. plasma levels. J Intern. Med., 259: 437–446.
  1323. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  1324. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  1325. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  1326. properties of HDL. Circ. Res., 95: 764–772.
  1327. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  1328. 1319–1333.
  1329. Am J Ophthalmol; 141:446–455.
  1330. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1331. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1332. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1333. properties of HDL. Circ. Res., 95: 764–772.
  1334. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  1335. 1319–1333.
  1336. Am J Ophthalmol; 141:446–455.
  1337. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  1338. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  1339. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1340. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1341. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1342. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1343. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  1344. J Neurosci 26: 1596–1603
  1345. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  1346. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  1347. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1348. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1349. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1350. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1351. Takahashi, M., Bujo H. and Shiba T. 2012. Enhanced circulating soluble LR11 in patients with diabetic
  1352. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis
  1353. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1354. cerebrospinal fluid of patients with Alzheimer disease. Dement. Geriatr. Cogn. Disord., 30: 28–32.
  1355. Imai, E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., Ura N., Kiyohara Y., Hirakata H., Watanabe T.,
  1356. plasma levels. J Intern. Med., 259: 437–446.
  1357. mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 23: 957–961
  1358. Shiba, T., Bujo H., Takahashi M. and Sato Y. 2013. Vitreous and circulating levels of soluble LR11,a novel,
  1359. Ting, H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., Knowlton A.A., Passerini A.G. and Simon S.I. 2007.
  1360. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1361. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1362. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1363. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  1364. J Neurosci 26: 1596–1603
  1365. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  1366. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  1367. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1368. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1369. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1370. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1371. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1372. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1373. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1374. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1375. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1376. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1377. Invest., 118: 2733–2746
  1378. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1379. Barter, P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. 2004. Anti-inflammatory
  1380. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1381. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1382. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1383. Bujo, H. and Saito Y. 2006. Modulation of smooth muscle cell migration by members of the low-density
  1384. Mida, T., Takahashi A. and Ikeuchi T. 2007. Prevention of stroke and dementia by statin therapy: experimental
  1385. Moriyama T., Ando Y., Inaguma D., Narita I., Iso H., Wakai K., Yasuda Y., Tsukamoto Y., Ito S., Makino H., Hishida
  1386. DCCT/EDIC cohort. Invest. Ophthalmol. Vis Sci., 45: 910–918.
  1387. patients with diabetic retinopathy. Am. J. Ophthalmol., 154: 187–192.
  1388. micro-vascular complications. JAMA; 303: 2291–2292.
  1389. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1390. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1391. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1392. A. and Matsuo S. 2007. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese
  1393. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1394. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1395. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1396. Invest., 118: 2733–2746
  1397. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1398. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1399. Invest., 118: 2733–2746
  1400. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1401. retinal microvascular function in people with diabetes Diabetes, 61: 1785- 1792.
  1402. factor-alpha. Circ. Res., 100: 381–390.
  1403. Takahashi, M., Bujo H., Shiba T., Jiang M., Maeno T. and Shirai K. 2012. Enhanced circulating soluble lr11 in
  1404. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1405. micro-vascular complications. JAMA; 303: 2291–2292.
  1406. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1407. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1408. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1409. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1410. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1411. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1412. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1413. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1414. microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903.
  1415. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1416. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1417. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1418. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1419. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1420. Scherzer, C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I. and Lah
  1421. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1422. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1423. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1424. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1425. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1426. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1427. micro-vascular complications. JAMA; 303: 2291–2292.
  1428. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1429. retinopathy. Am. J. Ophthalmol., 154: 187-192.
  1430. Ophthalmol. Vis. Sci., 49: 2679–2685.
  1431. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1432. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1433. Invest., 118: 2733–2746
  1434. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1435. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1436. micro-vascular complications. JAMA; 303: 2291–2292.
  1437. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1438. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1439. Tserentsoodol, N., Gordiyenko N.V., Pascual I., Lee J.W., Fliesler S.J. and Rodriguez I.R. 2006. Intraretinal lipid
  1440. Ikeuchi, T., Hirayama S., Miida T., Fukamachi I., Tokutake T., Ebinuma H., Takubo K., Kaneko H., Kasuga K.,
  1441. Rajala, U., Koskela P., Pajumppaa H. and Keinanen-Kiukaannieemi S. 2000. High cardiovascular disease
  1442. Takahashi, M., Bujo H., Jiang M., Noike H., Saito Y.and Shirai K. 2010. Enhanced circulating soluble LR11 in
  1443. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1444. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1445. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1446. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1447. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1448. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1449. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1450. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1451. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1452. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1453. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1454. Invest., 118: 2733–2746
  1455. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1456. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1457. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1458. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1459. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1460. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1461. Invest., 118: 2733–2746
  1462. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  1463. J Neurosci 26: 1596–1603
  1464. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  1465. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1466. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1467. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1468. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1469. factor-alpha. Circ. Res., 100: 381–390.
  1470. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1471. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1472. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1473. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1474. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1475. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1476. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1477. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1478. factor-alpha. Circ. Res., 100: 381–390.
  1479. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1480. Invest., 118: 2733–2746
  1481. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1482. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1483. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1484. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1485. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1486. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1487. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1488. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1489. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1490. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1491. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1492. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1493. Cheung, N., Mitchell P., Wong T.Y. 2010. Diabetic retinopathy. Lancet, 376: 124–136.
  1494. patients with chronic kidney disease. Clin. Exp. Nephrol., 11: 41–50.
  1495. Invest., 118: 2733–2746
  1496. Wong, T.Y., Klein R., Islam F.M., et al. 2006. Diabetic retinopathy in a multi-ethniccohort in the United States.
  1497. micro-vascular complications. JAMA; 303: 2291–2292.
  1498. and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 113: 378–393.
  1499. properties of HDL. Circ. Res., 95: 764–772.
  1500. Offe, K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I. and Lah J.J. 2006. The lipoprotein
  1501. 1319–1333.
  1502. Am J Ophthalmol; 141:446–455.
  1503. factor-alpha. Circ. Res., 100: 381–390.
  1504. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1505. patients with coronary organic stenosis. Atherosclerosis, 210: 581–584.
  1506. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1507. transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis., 12:
  1508. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1509. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1510. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1511. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1512. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  1513. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1514. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1515. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1516. Kakita A., Takahashi H., Bujo H., Saito Y., and Nishizawa M. 2010. Increasedlevels of soluble LR11 in
  1517. Simo, R., Garcia-Ramirez M., Higuera M. and Hernandez C. 2009. Apo-lipoprotein A1 is over-expressed in the
  1518. lipoprotein receptor family. Arterioscler Thromb Vasc Biol., 26: 1246–1252.
  1519. J.J. 2004. Loss of apolipoproteinE receptor LR11 in Alzheimer disease. Arch Neurol., 61: 1200–1205.
  1520. Cheung, N., Wong T.Y. 2009. Diabetic retinopathy and systemic complications. In Diabetic Retinopathy. Duh EJ,
  1521. Marcovina, S. and Packard C.J. 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B
  1522. receptor LR11 regulates amyloidbeta production and amyloid precursor protein traffic in endosomal compartments.
  1523. Sasongka, M.B., Wong T.Y., Nguyen T.T. and Kawasaki R. 2012. Serum apo-lipoproteins are associated with
  1524. marker for progression of diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2373-9.
  1525. Ed. Totowa, NJ, Humana Press, , p. 465–482
  1526. Kilpatrick, E.S., Rigby A.S. and Atkin S.L. 2009. Effect of glucose variability on the long-term risk of
  1527. Schneider W.J. and Saito Y. 2008. AngII-stimulated migration of vascular SMC is dependent on LR11. J. Clin.
  1528. Lyons, T.J., Jenkins A.J., Zheng D. et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the
  1529. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic
  1530. Jiang, M., Bujo H., Ohwaki K., Unoki H., Yamazaki H., Kanaki T., Shibasaki M., Azuma K., Harigaya K.,
  1531. J Neurosci 26: 1596–1603
  1532. retina of diabetic patients. Am. J. Ophthalmol., 147: 319–325 e311
  1533. Wu, M., Chen Y., Wilson K. et al. 2008. Intra-retinal leakage and oxidation of LDL in diabetic retinopathy. Invest.
  1534. Hirsch, I.B. and Brownlee M. 2010. Beyond hemoglobin A1c-need for additional markers of risk for diabetic

Article Post Production

    No data exists for the row/column.
Creative Commons License
Indian Streams Research Journal by Laxmi Book Publication is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://oldisrj.lbp.world/Default.aspx.
Permissions beyond the scope of this license may be available at http://oldisrj.lbp.world/Default.aspx
Copyright � 2014 Indian Streams Research Journal. All rights reserved
Looking for information? Browse our FAQs, tour our sitemap, or contact ISRJ
Read our Privacy Policy Statement and Plagairism Policy. Use of this site signifies your agreement to the Terms of Use